The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ECC 2015 | Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC

Name: Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC
Uploaded: 2015-09-26T00:00:00.000Z
Duration: 2 min 37 s
Description: At the European Cancer Congress (ECC) 2015, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomized phase 3 trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage IV non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.

Giorgio Scagliotti • 26 Sep 2015

ECC 2015

Lung Cancer Docetaxel Ramucirumab

At the European Cancer Congress (ECC) 2015, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomized phase 3 trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage IV non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.